Short Bowel Syndrome Market Report
First published: 21 October 2024 | Last updated: 28 May 2026 | Report Code: short-bowel-syndrome
Short Bowel Syndrome Market — USD 5.6 billion in 2023, Growing to USD 9.97B by 2033 at 5.8% CAGR
This report provides a comprehensive analysis of the Short Bowel Syndrome market, including market size, trends, segmentations, and forecasts from 2023 to 2033. It aims to deliver insights into the industry dynamics, regional performance, and key players shaping this market.
Key Takeaways
- Global market value rises from $5.60 Billion in 2023 to $9.97 Billion by 2033, reflecting a 5.8% CAGR over 2023 to 2033.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe and Asia Pacific show notable expansions: Europe from $1.59 Billion to $2.82 Billion, Asia Pacific from $1.17 Billion to $2.08 Billion.
- Core treatment categories include Nutritional Support, Pharmacological Therapy, and Surgical Options, with Hospitals and Home Care among end-user segments.
- Key players identified: Takeda Pharmaceutical Company, Nestlé Health Science, Baxter International, Boehringer Ingelheim, AbbVie Inc.
Short Bowel Syndrome Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The Short Bowel Syndrome market is positioned for sustained expansion as clinical needs and therapeutic options evolve. Market size grows from $5.60 Billion in 2023 to $9.97 Billion by 2033 at a 5.8% CAGR over 2023 to 2033. Demand is driven by better diagnosis, development of pharmacological therapies, nutritional and surgical management improvements, and increased awareness among clinicians and patients. North America is the largest regional market, supported by established clinical infrastructure and investment in treatment access. Europe, Asia Pacific, Latin America, and Middle East & Africa each contribute measurable growth based on regional healthcare developments. The report examines segmentation across treatment type, route of administration, age groups, and end users, and reviews strategic positions of leading companies including Takeda Pharmaceutical Company, Nestlé Health Science, Baxter International, Boehringer Ingelheim, and AbbVie Inc. Methodology integrates expert interviews, secondary literature, and data validation to present an evidence-based market narrative aimed at stakeholders evaluating opportunities and risks.
Key Growth Drivers
- Advances in pharmacological therapies and nutritional support expanding treatment options and clinical outcomes.
- Improved diagnostic awareness and earlier identification increasing patient access to specialized care pathways.
- Rising healthcare investments and infrastructure in key regions supporting wider availability of SBS management.
- Ongoing innovation in surgical techniques and supportive devices enabling broader therapeutic strategies.
- Growing clinical focus on diverse patient populations, including pediatric and geriatric groups, boosting demand for tailored solutions.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.60 Billion |
| CAGR (2023-2033) | 5.8% |
| 2033 Market Size | $9.97 Billion |
| Top Companies | Takeda Pharmaceutical Company, Nestlé Health Science, Baxter International, Boehringer Ingelheim, AbbVie Inc. |
| Published Date | 21 October 2024 |
| Last Modified Date | 28 May 2026 |
Short Bowel Syndrome Market Overview
Customize Short Bowel Syndrome Market Report market research report
- ✔ Get in-depth analysis of Short Bowel Syndrome market size, growth, and forecasts.
- ✔ Understand Short Bowel Syndrome's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Short Bowel Syndrome
What is the Market Size & CAGR of Short Bowel Syndrome Market Report market in 2023?
Short Bowel Syndrome Industry Analysis
Short Bowel Syndrome Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Short Bowel Syndrome Market Report Market Analysis Report by Region
Europe Short Bowel Syndrome Market Report:
Europe grows from $1.59 Billion in 2023 to $2.82 Billion in 2033. Growth is influenced by improving diagnostic practices, reimbursement frameworks, and ongoing development of therapeutic and nutritional solutions across member countries.Asia Pacific Short Bowel Syndrome Market Report:
Asia Pacific grows from $1.17 Billion in 2023 to $2.08 Billion in 2033. Market progress is driven by expanding healthcare access, rising clinical awareness, and adoption of pharmacological and nutritional interventions in growing medical centers.North America Short Bowel Syndrome Market Report:
North America is largest regional market, rising from $1.95 Billion in 2023 to $3.47 Billion in 2033. Regional drivers include established healthcare infrastructure, greater access to advanced therapies, and concentrated clinical expertise supporting SBS management.South America Short Bowel Syndrome Market Report:
Latin America grows from $0.29 Billion in 2023 to $0.51 Billion in 2033. Expansion reflects gradual improvements in healthcare delivery, increasing recognition of complex gastrointestinal conditions, and broader availability of supportive treatments.Middle East & Africa Short Bowel Syndrome Market Report:
Middle East and Africa grows from $0.61 Billion in 2023 to $1.09 Billion in 2033. Growth is supported by strengthened healthcare investments, rising specialist capacity, and enhanced access to surgical and nutritional management options.Tell us your focus area and get a customized research report.
Research Methodology
Short Bowel Syndrome Market Analysis By Treatment Type
The treatment type segment of the SBS market is dominated by Nutritional Support, which commands a market size of $3.65 billion in 2023 and is expected to reach $6.50 billion by 2033, comprising 65.19% of market share. The Pharmacological Therapy segment holds a market size of $1.38 billion in 2023 and $2.45 billion by 2033, maintaining 24.59% of market share. Additionally, Surgical Options make up the smallest segment with a market size of $0.57 billion in 2023, projected to grow to $1.02 billion by 2033, representing a 10.22% share.
Short Bowel Syndrome Market Analysis By Route Of Administration
When classified by route of administration, the oral route emerges as significant, projected to grow from $3.65 billion in 2023 to $6.50 billion by 2033, maintaining a share of 65.19%. The parenteral route exhibits market sizes of $1.38 billion in 2023, increasing to $2.45 billion by 2033, accounting for 24.59% of overall market share. The enteral administration holds $0.57 billion in 2023 and is estimated to reach $1.02 billion by 2033, comprising 10.22% share within the segment.
Short Bowel Syndrome Market Analysis By Age Group
Analyzing by age group, pediatric patients are forecasted to dominate with a market size of $3.65 billion in 2023 and anticipated growth to $6.50 billion by 2033, representing 65.19% of market share. Adult patients measure $1.38 billion in 2023, expected to increase to $2.45 billion by 2033, making up 24.59%. Geriatric individuals have a market size of $0.57 billion in 2023, projected to reach $1.02 billion by 2033, constituting a 10.22% share.
Short Bowel Syndrome Market Analysis By End User
Within the end-user segment, hospitals are the leading sector, boasting a market size of $3.65 billion in 2023, expanding to $6.50 billion by 2033 with a consistent share of 65.19%. Home care services hold $1.38 billion in 2023, expected to rise to $2.45 billion by 2033, accounting for 24.59%, while specialty clinics capture $0.57 billion in 2023 with projections up to $1.02 billion by 2033, making up 10.22%.
Short Bowel Syndrome Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Short Bowel Syndrome Industry
Takeda Pharmaceutical Company:
Takeda focuses on innovative gastroenterology therapies, including treatments for Short Bowel Syndrome, emphasizing research in conditions that impact intestinal function.Nestlé Health Science:
Nestlé Health Science develops nutritional solutions targeting SBS management, providing advanced enteral and parenteral nutrition products for patients.Baxter International:
Baxter International specializes in medical devices and therapies, with a significant offering in parenteral solutions for patients with SBS.Boehringer Ingelheim:
Boehringer operates in the pharmaceutical sector, focusing on treatment advancements that aid those suffering from Short Bowel Syndrome.AbbVie Inc.:
AbbVie invests heavily in biopharmaceutical research, delivering therapies that positively influence the lives of patients with intestinal diseases.We're grateful to work with incredible clients.
FAQs
What is the current market size of Short Bowel Syndrome?
The market size for Short Bowel Syndrome was $5.60 Billion in 2023, per the report data, reflecting baseline valuation used for the 2023 to 2033 forecast period.
How big will the Short Bowel Syndrome market be in 2033?
The market is projected to reach $9.97 Billion by 2033, representing the end-point valuation for the forecast period of 2023 to 2033 provided in the report.
What is CAGR of the Short Bowel Syndrome market?
The reported compound annual growth rate (CAGR) for the market is 5.8% for the forecast period spanning 2023 to 2033, as presented in the study data.
Is there a single fastest Growing region in the Short Bowel Syndrome Market Report market?
No single fastest-growing region is stated for the Short Bowel Syndrome Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which treatment types are included in the market segmentation?
Treatment segmentation includes Nutritional Support, Pharmacological Therapy, and Surgical Options, reflecting primary therapeutic approaches listed in the report's structure.
Who are the leading companies in the Short Bowel Syndrome market?
Top companies named in the report are Takeda Pharmaceutical Company, Nestlé Health Science, Baxter International, Boehringer Ingelheim, and AbbVie Inc.
What end users are covered in the market segments?
End-user segments specified include Hospitals, Home Care, and Specialty Clinics, indicating primary channels where SBS treatment and management occur.
How is age Group segmentation presented in the report?
Age-group segmentation is detailed as Pediatric, Adult, and Geriatric, capturing distinct demographic cohorts addressed by therapeutic and care pathways in the market.